VEGF-targeted therapy: therapeutic potential and recent advances

Area of Science:

• Oncology
• Vascular Biology
• Pharmacology

Background:

• Tumor growth necessitates angiogenesis, the formation of new blood vessels.
• Vascular endothelial growth factor (VEGF) and its receptors are critical regulators of angiogenesis.
• Angiogenesis inhibitors represent a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

• To review recent advancements in the clinical application of angiogenesis inhibitors for cancer therapy.
• To highlight the role of VEGF-targeted agents in treating specific cancers.

Main Methods:

• Literature review of recent studies on angiogenesis inhibitors.
• Focus on clinical developments and therapeutic applications.
• Analysis of VEGF-targeted agents in breast, lung, and colorectal cancer treatment.

Main Results:

• Angiogenesis inhibitors have transitioned from theoretical concepts to practical anticancer treatments.
• VEGF-targeted therapies are under extensive investigation for various malignancies.
• Significant progress has been made in applying these inhibitors to breast, lung, and colorectal cancers.

Conclusions:

• Angiogenesis inhibition is a validated approach in oncology.
• VEGF pathway inhibitors offer a targeted strategy for cancer therapy.
• Ongoing research continues to refine the use of these inhibitors in clinical practice.